Tango Therapeutics TNGX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Business | ||||||
| Discovery Direct Program Expenses-RD | $1.87M-60.0% | $1.28M-71.7% | $1.5M-78.2% | $2.71M-63.9% | $4.68M-15.1% | |
| Facilities And Other Related Expenses-RD | $4.34M-20.6% | $4.67M+31.7% | $4.9M-2.9% | $5.43M+0.3% | $5.47M+12.1% | |
| Personnel-Related Expenses-RD | $12.93M-6.6% | $12.41M-5.6% | $12.38M-0.2% | $12.83M-2.1% | $13.85M+8.2% | |
| TNG260Direct Program Expenses-RD | $2.01M+16.1% | $1.08M-25.1% | $1.66M-14.5% | $1.81M-51.9% | $1.73M-22.6% | |
| TNG456Direct Program Expenses-RD | $2.06M+55.8% | $1.59M-64.9% | $2M— | $1.65M— | $1.32M— | |
| TNG908Direct Program Expenses-RD | $581K-66.1% | $845K-69.9% | $1.23M-62.1% | $1.24M-62.1% | $1.71M-59.8% | |
| TNG961Direct Program Expenses-RD | $408K-81.6% | $813K— | $1.07M— | $1.57M— | $2.22M— | |
| Vopimetostat Direct Program Expenses-RD | $9.33M+70.9% | $9.41M+135% | $6.07M+94.6% | $5.58M— | $5.46M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Tango Therapeutics break its business down?
- Tango Therapeutics (TNGX) reports research and development expense by business across 8 parts — Discovery Direct Program Expenses-RD, Facilities And Other Related Expenses-RD, Personnel-Related Expenses-RD, TNG260Direct Program Expenses-RD and TNG456Direct Program Expenses-RD. Each is extracted from the segment footnotes and tracked over time.
- Where does Tango Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Tango Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.